Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2021-03-29 Director's Dealing
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-03-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-29 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-16 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the company posted a presentation on its website and attached it as Exhibit 99.1 titled 'Corporate Overview Presentation, March 2021'. The document explicitly states that the information is furnished under Item 7.01 Regulation FD Disclosure and is not considered filed for certain legal purposes. The content is primarily about the disclosure of a presentation rather than the presentation itself or a detailed financial report. The document length is 3433 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP) announcement within a Form 8-K. Given the nature of the document and the clear reference to a presentation, the classification is Investor Presentation (IP) with high confidence.
2021-03-09 English
FORM 4 SUBMISSION
Director's Dealing
2021-03-08 English
Director's Dealing 2021
Director's Dealing
2021-03-04 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.